Glaucoma Eye Drops Market Synopsis:
Glaucoma Eye Drops Market Size Was Valued at USD 9.03 Billion in 2023, and is Projected to Reach USD 13.57 Billion by 2032, Growing at a CAGR of 4.63 % From 2024-2032.
The Glaucoma Eye Drops Market is focused on drugs used by glaucoma patients at risk of losing sight due to optic nerve deterioration and elevated intraocular pressure (IOP). Therefore, these eye drops like those of the class of prostaglandin analogs, beta-blockers, and carbonic anhydrase inhibitors are useful in either stopping or delaying the progression, especially oAG and PACG.
The glaucoma eye drops market trend is that it has experienced a steady growth over the years because glaucoma is the second largest cause of blindness. Most people are getting glaucoma as they grow older, are diabetics or hypertensive hence increasing the need for effective control of glaucoma. Surprisingly of equal importance, the market of glaucoma eye drops is also experiencing the light from the heightened perception of the importance of early diagnosis and treatment.
Newly launched formulations preservative-free drops, and combination therapies were launched with enhanced care in patient compliance and effectiveness of the treatment in the overall management of eye disorder and the industry has been dedicatedly investing on Research & development. Foreign policies of governments in the countries – particularly reimbursement policies in the developed world – and the ensures availability of the medicine have also boosted the use of the glaucoma medications. Owing to the growing population of awareness campaigns and screening programs, there is potential for growth in the market during the future years.
Glaucoma Eye Drops Market Trend Analysis:
Rise of Combination Therapies for Enhanced Efficacy
- A combination therapy is currently slowly evolving as the common method of treatment of glaucoma via eye drops. These therapies originate when two or more drugs with therapeutic effects are incorporated into one formulation which is convenient for the patient and less contributes to compliance. Better compliance has been noted due to the merge of prostaglandin analogs with beta-blockers or alpha agonists as they are more effective than the use of single agents for lowering IOP.A great deal of capital is being invested into the development of these combination drops by players in the pharmaceutical industry due to the challenges posed by the current therapies. It is consistent with increasing demand for side-effect-free applications and easier management of the chronic glaucoma type.
Expansion of Distribution Channels in Emerging Markets
- The four opportunities for glaucoma eye drops are the stabilization in the United States, the expansion into developed Asian countries, the new opportunity in the emerging markets. Thus, there are reasonable grounds for the development of the glaucoma therapies market, increased levels of incidence of Glaucoma, particularly in Asia-Pacific and Latin American countries, and improved healthcare facilities.This has made manufacturers of pharmaceutical product to look at the local distributors as partners in enhancing their operations in these markets. Moreover, e-commerce increased the convenience of the patients in acquisition of medicine especially in rural areas. Subsidized by the government and increased health care consciousness is also helping to widen the availability and cheapness of glaucoma treatment and its range in these areas.
Glaucoma Eye Drops Market Segment Analysis:
The Glaucoma Eye Drops Market is Segmented on the basis of Drug Type, Disease Indication, Distribution Channel, and Region.
By Drug Type, the Prostaglandin analogs segment is expected to dominate the market during the forecast period
- Over the same period, the Market is expected to enlarge its prostaglandin analogs segment in the glaucoma eye drops market in the future. These drugs provide a good influence in moderating the intraocular pressure by elevating the clearance of the aqueous humor and thus it is the first choice for managing glaucoma. Both patients and physicians appreciate these agents as they require once-a-day administration and have few if any, major side effects that are not classed as systemic. Despite the presence of other classes of glaucoma drugs, Latanoprost, bimatoprost, and travoprost prostaglandin analogs are more effective. Further, continuing formulation innovations such as preservative-free formulations are forecasted to reduce the total amount of ocular discomfort and enhance patients' interface thus strengthening the segment.
By Disease Indication, the Open-angle Glaucoma segment is expected to hold the largest share
- These two prescriptions for open-angle glaucoma take the entire lion share in the glaucoma eye drops market because open-angle glaucoma is the dominant type of the disease in the entire world. Mentioning the pressure in the eye momentarily and increasing gradually, this illness may be asymptomatic for many years, until the vision deteriorates significantly. The segment has a wide range of treatment for open-angle glaucoma, increasing knowledge of the disease, and regular eye check-ups also positively influence the segment’s development. The advancement in Technology in diagnosing for instance OCT has improved the ability of detecting open angle glaucoma therefore prevent and increase the use of eye drop.
Glaucoma Eye Drops Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- It has been analyzed that North America will show the largest demand or glaucoma eye drops due to the rise in cases of glaucoma and developed healthcare facilities in the region. The United States has a particularly large share because its population is aging and because both diabetes and high blood pressure are glaucoma risk factors. More specifically, the market was and still is dominated by these leading participants, while the key pharmaceutical companies’ investment in R&D was illustrated repeatedly by the incessant emphasis on the development of innovative products. Better reimbursement and diagnostic and treatment facilities are some of the others which help to increase the growth of this market.
- Additionally, there are some other factors for instance availability of agencies and campaigns aimed at making people to go for regular eye check-ups and glaucoma detected in its initial stage contributed to placing the region at the first instance. Canada is also targeting North America because of its ‘healing for all campaign and competitively priced Acular eye therapy for glaucoma. Increased marketing in e-Telemedine and e-prescribing have enhanced access to, and adherence to, treatments and was another driver in the region.
Active Key Players in the Glaucoma Eye Drops Market:
- AbbVie Inc. (United States)
- Aerie Pharmaceuticals (United States)
- Allergan (United States)
- Bausch + Lomb (United States)
- Chengdu Kanghong Pharmaceutical Group (China)
- Cipla Limited (India)
- EyePoint Pharmaceuticals (United States)
- Merck & Co., Inc. (United States)
- Novartis AG (Switzerland)
- Pfizer Inc. (United States)
- Santen Pharmaceutical Co., Ltd. (Japan)
- Senju Pharmaceutical Co., Ltd. (Japan)
- Sun Pharmaceutical Industries Ltd. (India)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Zydus Cadila (India)
- Other Active Players
|
Glaucoma Eye Drops Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 9.03 Billion |
|
Forecast Period 2024-32 CAGR: |
4.63 % |
Market Size in 2032: |
USD 13.57 Billion |
|
Segments Covered: |
By Drug Type |
|
|
|
By Disease Indication |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Glaucoma Eye Drops Market by Drug Type
4.1 Glaucoma Eye Drops Market Snapshot and Growth Engine
4.2 Glaucoma Eye Drops Market Overview
4.3 Prostaglandin analogs Beta blockers Alpha agonists Carbonic Anhydrase Inhibitors (CAIs) Combined Medications Others (rho-kinase inhibitor
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Prostaglandin analogs Beta blockers Alpha agonists Carbonic Anhydrase Inhibitors (CAIs) Combined Medications Others (rho-kinase inhibitor: Geographic Segmentation Analysis
4.4 Cholinergic agonists)
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Cholinergic agonists): Geographic Segmentation Analysis
Chapter 5: Glaucoma Eye Drops Market by Disease Indication
5.1 Glaucoma Eye Drops Market Snapshot and Growth Engine
5.2 Glaucoma Eye Drops Market Overview
5.3 Angle-closure Glaucoma Open-angle Glaucoma
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Angle-closure Glaucoma Open-angle Glaucoma: Geographic Segmentation Analysis
Chapter 6: Glaucoma Eye Drops Market by Distribution Channel
6.1 Glaucoma Eye Drops Market Snapshot and Growth Engine
6.2 Glaucoma Eye Drops Market Overview
6.3 Hospital Pharmacy Retail Pharmacy Online Pharmacy
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital Pharmacy Retail Pharmacy Online Pharmacy: Geographic Segmentation Analysis
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Benchmarking
7.1.2 Glaucoma Eye Drops Market Share by Manufacturer (2023)
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Mergers and Acquisitions
7.2 ABBVIE INC. (UNITED STATES)
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Role of the Company in the Market
7.2.5 Sustainability and Social Responsibility
7.2.6 Operating Business Segments
7.2.7 Product Portfolio
7.2.8 Business Performance
7.2.9 Key Strategic Moves and Recent Developments
7.2.10 SWOT Analysis
7.3 AERIE PHARMACEUTICALS (UNITED STATES)
7.4 ALLERGAN (UNITED STATES)
7.5 BAUSCH + LOMB (UNITED STATES)
7.6 CHENGDU KANGHONG PHARMACEUTICAL GROUP (CHINA)
7.7 CIPLA LIMITED (INDIA)
7.8 EYEPOINT PHARMACEUTICALS (UNITED STATES)
7.9 MERCK & CO. INC. (UNITED STATES)
7.10 NOVARTIS AG (SWITZERLAND)
7.11 PFIZER INC. (UNITED STATES)
7.12 SANTEN PHARMACEUTICAL CO. LTD. (JAPAN)
7.13 SENJU PHARMACEUTICAL CO. LTD. (JAPAN)
7.14 SUN PHARMACEUTICAL INDUSTRIES LTD. (INDIA)
7.15 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
7.16 ZYDUS CADILA (INDIA)
7.17 OTHER ACTIVE PLAYERS
Chapter 8: Global Glaucoma Eye Drops Market By Region
8.1 Overview
8.2. North America Glaucoma Eye Drops Market
8.2.1 Key Market Trends, Growth Factors and Opportunities
8.2.2 Top Key Companies
8.2.3 Historic and Forecasted Market Size by Segments
8.2.4 Historic and Forecasted Market Size By Drug Type
8.2.4.1 Prostaglandin analogs Beta blockers Alpha agonists Carbonic Anhydrase Inhibitors (CAIs) Combined Medications Others (rho-kinase inhibitor
8.2.4.2 Cholinergic agonists)
8.2.5 Historic and Forecasted Market Size By Disease Indication
8.2.5.1 Angle-closure Glaucoma Open-angle Glaucoma
8.2.6 Historic and Forecasted Market Size By Distribution Channel
8.2.6.1 Hospital Pharmacy Retail Pharmacy Online Pharmacy
8.2.7 Historic and Forecast Market Size by Country
8.2.7.1 US
8.2.7.2 Canada
8.2.7.3 Mexico
8.3. Eastern Europe Glaucoma Eye Drops Market
8.3.1 Key Market Trends, Growth Factors and Opportunities
8.3.2 Top Key Companies
8.3.3 Historic and Forecasted Market Size by Segments
8.3.4 Historic and Forecasted Market Size By Drug Type
8.3.4.1 Prostaglandin analogs Beta blockers Alpha agonists Carbonic Anhydrase Inhibitors (CAIs) Combined Medications Others (rho-kinase inhibitor
8.3.4.2 Cholinergic agonists)
8.3.5 Historic and Forecasted Market Size By Disease Indication
8.3.5.1 Angle-closure Glaucoma Open-angle Glaucoma
8.3.6 Historic and Forecasted Market Size By Distribution Channel
8.3.6.1 Hospital Pharmacy Retail Pharmacy Online Pharmacy
8.3.7 Historic and Forecast Market Size by Country
8.3.7.1 Bulgaria
8.3.7.2 The Czech Republic
8.3.7.3 Hungary
8.3.7.4 Poland
8.3.7.5 Romania
8.3.7.6 Rest of Eastern Europe
8.4. Western Europe Glaucoma Eye Drops Market
8.4.1 Key Market Trends, Growth Factors and Opportunities
8.4.2 Top Key Companies
8.4.3 Historic and Forecasted Market Size by Segments
8.4.4 Historic and Forecasted Market Size By Drug Type
8.4.4.1 Prostaglandin analogs Beta blockers Alpha agonists Carbonic Anhydrase Inhibitors (CAIs) Combined Medications Others (rho-kinase inhibitor
8.4.4.2 Cholinergic agonists)
8.4.5 Historic and Forecasted Market Size By Disease Indication
8.4.5.1 Angle-closure Glaucoma Open-angle Glaucoma
8.4.6 Historic and Forecasted Market Size By Distribution Channel
8.4.6.1 Hospital Pharmacy Retail Pharmacy Online Pharmacy
8.4.7 Historic and Forecast Market Size by Country
8.4.7.1 Germany
8.4.7.2 UK
8.4.7.3 France
8.4.7.4 Netherlands
8.4.7.5 Italy
8.4.7.6 Russia
8.4.7.7 Spain
8.4.7.8 Rest of Western Europe
8.5. Asia Pacific Glaucoma Eye Drops Market
8.5.1 Key Market Trends, Growth Factors and Opportunities
8.5.2 Top Key Companies
8.5.3 Historic and Forecasted Market Size by Segments
8.5.4 Historic and Forecasted Market Size By Drug Type
8.5.4.1 Prostaglandin analogs Beta blockers Alpha agonists Carbonic Anhydrase Inhibitors (CAIs) Combined Medications Others (rho-kinase inhibitor
8.5.4.2 Cholinergic agonists)
8.5.5 Historic and Forecasted Market Size By Disease Indication
8.5.5.1 Angle-closure Glaucoma Open-angle Glaucoma
8.5.6 Historic and Forecasted Market Size By Distribution Channel
8.5.6.1 Hospital Pharmacy Retail Pharmacy Online Pharmacy
8.5.7 Historic and Forecast Market Size by Country
8.5.7.1 China
8.5.7.2 India
8.5.7.3 Japan
8.5.7.4 South Korea
8.5.7.5 Malaysia
8.5.7.6 Thailand
8.5.7.7 Vietnam
8.5.7.8 The Philippines
8.5.7.9 Australia
8.5.7.10 New Zealand
8.5.7.11 Rest of APAC
8.6. Middle East & Africa Glaucoma Eye Drops Market
8.6.1 Key Market Trends, Growth Factors and Opportunities
8.6.2 Top Key Companies
8.6.3 Historic and Forecasted Market Size by Segments
8.6.4 Historic and Forecasted Market Size By Drug Type
8.6.4.1 Prostaglandin analogs Beta blockers Alpha agonists Carbonic Anhydrase Inhibitors (CAIs) Combined Medications Others (rho-kinase inhibitor
8.6.4.2 Cholinergic agonists)
8.6.5 Historic and Forecasted Market Size By Disease Indication
8.6.5.1 Angle-closure Glaucoma Open-angle Glaucoma
8.6.6 Historic and Forecasted Market Size By Distribution Channel
8.6.6.1 Hospital Pharmacy Retail Pharmacy Online Pharmacy
8.6.7 Historic and Forecast Market Size by Country
8.6.7.1 Turkey
8.6.7.2 Bahrain
8.6.7.3 Kuwait
8.6.7.4 Saudi Arabia
8.6.7.5 Qatar
8.6.7.6 UAE
8.6.7.7 Israel
8.6.7.8 South Africa
8.7. South America Glaucoma Eye Drops Market
8.7.1 Key Market Trends, Growth Factors and Opportunities
8.7.2 Top Key Companies
8.7.3 Historic and Forecasted Market Size by Segments
8.7.4 Historic and Forecasted Market Size By Drug Type
8.7.4.1 Prostaglandin analogs Beta blockers Alpha agonists Carbonic Anhydrase Inhibitors (CAIs) Combined Medications Others (rho-kinase inhibitor
8.7.4.2 Cholinergic agonists)
8.7.5 Historic and Forecasted Market Size By Disease Indication
8.7.5.1 Angle-closure Glaucoma Open-angle Glaucoma
8.7.6 Historic and Forecasted Market Size By Distribution Channel
8.7.6.1 Hospital Pharmacy Retail Pharmacy Online Pharmacy
8.7.7 Historic and Forecast Market Size by Country
8.7.7.1 Brazil
8.7.7.2 Argentina
8.7.7.3 Rest of SA
Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies
Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research
|
Glaucoma Eye Drops Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 9.03 Billion |
|
Forecast Period 2024-32 CAGR: |
4.63 % |
Market Size in 2032: |
USD 13.57 Billion |
|
Segments Covered: |
By Drug Type |
|
|
|
By Disease Indication |
|
||
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
